Last €3.66 EUR
Change Today +0.025 / 0.69%
Volume 601.1K
As of 1:58 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Open
€3.66
Previous Close
€3.63
Day High
€3.73
Day Low
€3.59
52 Week High
11/5/13 - €5.18
52 Week Low
04/24/13 - €2.15
Market Cap
480.7M
Average Volume 10 Days
991.0K
EPS TTM
€-0.21
Shares Outstanding
131.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG, together with its subsidiaries, provides drug discovery solutions for pharmaceutical and biotechnology companies, and academic institutions worldwide. Its services comprise target ID and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism and excretion) profiling, proteomics, reagent production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage comprising DiaPep277 for diabetes type 1; EVT3021 for Alzheimer's disease; EVT201 for insomnia; Somatoprim for Acromegaly; EVT1032 for TRD; EVT401 inflammation; and ND³ for oncology. It also has various pre-clinical stage products, including ND³ for pain and oncology; endometriosis products; and EVT770 for diabetes type 2/1, as well as discovery stage products comprising EVT070 for diabetes type 2; and various products for inflammation, diabetes type 2, diabetes type 2/1, kidney disease, and Alzheimer’s disease. The company has alliances and partnerships with various companies comprising AstraZeneca AB, Bayer Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., the Jain Foundation, Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Ono Pharmaceutical Co., Ltd., and UCB Pharma. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

610 Employees
Last Reported Date: 03/25/14
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: €601.0K
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €360.0K
Chief Operating Officer and Member of the Man...
Total Annual Compensation: €409.0K
Chief Scientific Officer and Member of the Ma...
Total Annual Compensation: €372.0K
Compensation as of Fiscal Year 2013.

evotec ag (EVT) Key Developments

Evotec AG Signs Research Collaboration and Licensing Agreement with Debiopharm Group

Evotec AG announced a research collaboration and licensing agreement with Debiopharm Group to identify and develop novel compounds to treat multiple forms of solid tumours and leukaemias with defined genetic alterations. Discovery and preclinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products. This programme is based on Evotec's drug discovery efforts to investigate genetically altered targets whose 'driver' role in several cancer types has been validated and on the shared objective of identifying novel therapeutic agents in a variety of cancers, including AML (Acute Myeloid Leukaemia), prostate cancer and glioblastoma.

Evotec Enters into Research Collaboration and Licensing Deal with Debiopharm Group to Identify and Develop New Cancer Treatments

Evotec has entered into a research collaboration and licensing deal with Debiopharm Group to identify and develop new compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations. Under the deal, Evotec will be responsible for discovery and pre-clinical development efforts, while Debiopharm will manage clinical development. The deal will see Evotec receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products. The project is based on Evotec's drug discovery efforts to investigate genetically altered targets whose 'driver' role in several cancer types has been validated and on the shared objective of discovering new therapeutic agents in a variety of cancers such as acute myeloid leukemia (AML), prostate cancer and glioblastoma.

Evotec AG and Debiopharm Group to Collaborate on Development of New Treatment for Cancer

Evotec AG announced a research collaboration and licensing deal with Debiopharm Group, Lausanne, Switzerland. The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations. Discovery and pre-clinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €3.66 EUR +0.025

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.80 USD +0.02
Cell Therapeutics Inc $3.18 USD -0.15
Cytokinetics Inc $11.92 USD -0.0199
Exelixis Inc $3.45 USD -0.13
Galapagos NV €16.00 EUR -0.01
View Industry Companies
 

Industry Analysis

EVT

Industry Average

Valuation EVT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit www.evotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.